Yoichi Osako
Overview
Explore the profile of Yoichi Osako including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tsuruda M, Yoshino H, Okamura S, Kuroshima K, Osako Y, Sakaguchi T, et al.
PLoS One
. 2020 May;
15(5):e0232545.
PMID: 32379831
Exosomes are 40-100 nm nano-sized extracellular vesicles. They are released from many cell types and move into the extracellular space, thereby transferring their components to recipient cells. Exosomes are receiving...
12.
Kuroshima K, Yoshino H, Okamura S, Tsuruda M, Osako Y, Sakaguchi T, et al.
Cancer Sci
. 2020 Apr;
111(5):1607-1618.
PMID: 32232883
Sunitinib, a multitargeted receptor tyrosine kinase inhibitor including vascular endothelial growth factor, has been widely used as a first-line treatment against metastatic renal cell carcinoma (mRCC). However, mRCC often acquires...
13.
Okubo A, Fujii K, Tada K, Higashi Y, Hirohata Y, Osako Y, et al.
J Dermatol
. 2019 Oct;
47(1):e33-e34.
PMID: 31612548
No abstract available.
14.
Osako Y, Yoshino H, Sakaguchi T, Sugita S, Yonemori M, Nakagawa M, et al.
Int J Oncol
. 2019 Mar;
54(5):1759-1770.
PMID: 30816432
Sunitinib is the most common primary molecular‑targeted agent for metastatic clear cell renal cell carcinoma (ccRCC); however, intrinsic or acquired sunitinib resistance has become a significant problem in medical practice....
15.
Sugita S, Enokida H, Yoshino H, Miyamoto K, Yonemori M, Sakaguchi T, et al.
Int J Oncol
. 2018 Jun;
53(2):725-736.
PMID: 29901113
The active form of the small GTPase RAS binds to downstream effectors to promote cell growth and proliferation. RAS signal enhancement contributes to tumorigenesis, invasion, and metastasis in various different...
16.
Sakaguchi T, Yoshino H, Sugita S, Miyamoto K, Yonemori M, Osako Y, et al.
Oncotarget
. 2018 May;
9(33):23003-23017.
PMID: 29796168
Sunitinib is a standard molecular-targeted drug used as a first-line treatment for metastatic clear cell renal cell carcinoma (ccRCC); however, resistance to sunitinib has become a major problem in medical...
17.
Osako Y, Tatarano S, Nishiyama K, Yamada Y, Yamagata T, Uchida Y, et al.
Int J Urol
. 2011 May;
18(7):533-5.
PMID: 21569110
We describe a case of intraparenchymal renal artery aneurysm in a 58-year-old normotensive man with a history of distal ureterectomy. Imaging studies of the pre-existing right renal mass had been...